INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 78 filers reported holding INOZYME PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,353,974 | +148.2% | 2,465,232 | +229.2% | 0.00% | – |
| Q2 2023 | $4,171,005 | -48.2% | 748,834 | -46.7% | 0.00% | – |
| Q1 2023 | $8,056,334 | +393.3% | 1,405,992 | +130.7% | 0.00% | – |
| Q3 2022 | $1,633,000 | -43.9% | 609,380 | -0.1% | 0.00% | – |
| Q2 2022 | $2,909,000 | +16.7% | 609,819 | +0.0% | 0.00% | – |
| Q1 2022 | $2,493,000 | -40.0% | 609,594 | +0.0% | 0.00% | – |
| Q4 2021 | $4,156,000 | -41.2% | 609,380 | 0.0% | 0.00% | -100.0% |
| Q3 2021 | $7,063,000 | -32.0% | 609,380 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $10,384,000 | -13.9% | 609,380 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $12,066,000 | -4.1% | 609,380 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $12,578,000 | -21.5% | 609,380 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $16,021,000 | – | 609,380 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $10,852,000 | 4.54% |
| CHI Advisors LLC | 892,057 | $6,084,000 | 2.02% |
| Sofinnova Investments, Inc. | 2,028,308 | $13,833,000 | 0.81% |
| MPM BioImpact LLC | 302,615 | $2,064,000 | 0.38% |
| NEA Management Company, LLC | 2,444,379 | $16,671,000 | 0.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $15,991,000 | 0.34% |
| Rock Springs Capital Management LP | 868,466 | $5,923,000 | 0.14% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,013,216 | $6,910,000 | 0.13% |
| Orbimed Advisors | 526,600 | $3,591,000 | 0.05% |
| Overbrook Management Corp | 16,726 | $114,000 | 0.02% |